Novel antipsychotics and the problem of clinical stabilization in schizophrenia: Are they ''stabilizer'' rather than typical compounds?

被引:18
作者
Altamura, AC
机构
关键词
D O I
10.1097/00004850-199609000-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:153 / 155
页数:3
相关论文
共 24 条
[1]  
Altamura A. C., 1991, BIOL PSYCHIAT, V1, P583
[2]  
ALTAMURA AC, 1989, PHARMACOPSYCHIATRY, V22, P246
[3]   Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: A study with haloperidol decanoate [J].
Altamura, AC ;
Tacchini, GL ;
Maes, M .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1995, 5 :55-58
[4]  
ALTAMURA AC, 1992, SCHIZOPHR RES, V8, P187
[5]  
ALTAMURA AC, 1996, IN PRESS PSYCHOPHARM
[6]   HALOPERIDOL DECANOATE IN CHRONIC-SCHIZOPHRENIA - A STUDY OF 12 MONTHS WITH PLASMA-LEVELS [J].
ALTAMURA, CA ;
COLACURCIO, F ;
MAURI, MC ;
MORO, AR ;
DENOVELLIS, F .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1990, 14 (01) :25-35
[7]  
ALTAMURA CA, 1993, AM J PSYCHIAT, V150, P1731
[8]  
ANDREASEN NC, 1995, ARCH GEN PSYCHIAT, V52, P341
[9]  
ARNDT S, 1995, ARCH GEN PSYCHIAT, V52, P352
[10]  
CARLSSON A, 1995, EUROPEAN NEUROPSYCHO, V5, P160